Stock Ratings / Health Care / NIVF / earnings

MGRX (34) CCEL (64) PARK (49) VMD (69) ⌘ Pro Terminal →

NewGenIvf Group Limited (Class A) (NIVF) Next Earnings Date & Expected ±12.5% Move

Q: When is NIVF's next earnings date?

Based on SEC filing cadence, NewGenIvf Group Limited (Class A) (NIVF)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is NIVF stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for NIVF, spanning a range between $1 and $1.28.

$1.14 -5.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

NewGenIvf Group Limited (Class A) (NIVF) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $11.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NIVF)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.14 Expected Swing

MODEL EARNINGS SETUP GAUGE

NIVF Quantitative Pre-Earnings Setup: 22/100

Trailing EPS: $4.25 • YoY Revenue Growth: -13%

Model Bullish Setup (22/100)Model Risk Weight (78/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$4.7M	$9.9M	-$11.1M	20.2%
FY 2024	2024-12-31	$5.4M	-$524.6K	-$8.3M	33.6%
FY 2023	2023-12-31	$5.1M	$130.2K	-$1.8M	20.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NIVF)

✓Walkthrough of NIVF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NIVF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.77%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.04H $1.14L $0.96C $1.14VOL 167.9K

SUP: $-11.60SMA50: $18.44SMA200: $396.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NIVF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NIVF Butterfly Map → + Track NIVF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NIVF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NIVF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NIVF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NIVF)

Health Care Rank #1007 of 1016 ⚔️ MGRX vs NIVF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NIVF vs. MGRX, CCEL, PARK, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NewGenIvf Group Limited (Class A) (NIVF) ranks #1007 by composite RQD confidence (22/100, grade E) and #887 by equity capitalization ($11.3M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with NIVF at 22/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NIVF ACTIVE NewGenIvf Group Limited (Class A)	E	22/100	—	—	-32.8%	-5.00%	$11.3M	Benchmark Subject
MGRX Mangoceuticals Inc.	E	34/100	—	54.9%	-35.0%	-1.47%	$5.7M	/mgrx-vs-nivf →
CCEL Cryo-Cell International Inc.	C	64/100	—	—	18.2%	+1.17%	$41.8M	/ccel-vs-nivf →
PARK Park Dental Partners Inc.	D	49/100	—	—	—	-2.79%	$95.4M	/park-vs-nivf →
VMD Viemed Healthcare Inc.	C+	69/100	24.6x	57.5%	13.0%	-0.40%	$379.0M	/vmd-vs-nivf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001981662

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NewGenIvf Group Limited (Class A) (NIVF) reported GAAP revenue of $4.7M (-13.0% vs. FY2024 revenue of $5.4M , and -8.0% cumulative change since FY2023) , GAAP net income of $9.9M, operating cash flow of -$10.9M, and free cash flow of -$11.1M (-33.0% YoY). On the balance sheet, NIVF closed FY2025 with $32.7M in total assets against $0 in total debt (Altman Z-Score: 0.63, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.7M	$9.9M	-$10.9M	-$11.1M	$32.7M	—
FY2024 (FY)	2024-12-31	$5.4M	-$524.6K	-$8.3M	-$8.3M	$3.6M	—
FY2023 (FY)	2023-12-31	$5.1M	$130.2K	-$1.8M	-$1.8M	—	—

3. NIVF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NIVF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NewGenIvf Group Limited (Class A) (NASDAQ: NIVF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $1.14 (-5.00% 1D, market cap $11.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NIVF ranks #1007 in composite RQD confidence.

How does NIVF compare to MGRX and CCEL in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), NIVF carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.8%. By comparison, MGRX (Mangoceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M) and CCEL (Cryo-Cell International Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 18.2%, cap $41.8M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NIVF?

Per NIVF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001981662), NewGenIvf Group Limited (Class A) generated $4.7M in revenue (-13.0% YoY), $9.9M in net income, and -$11.1M in free cash flow against $32.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NIVF trading relative to its 50-day, 200-day, and 52-week technical levels?

NIVF last traded at $1.14 (-5.00% on volume of 284,413 shares), positioning the stock -93.82% below its 50-day simple moving average ($18.44) and -99.71% below its 200-day simple moving average ($396.58). Across its 52-week range of $0.96 to $20,908.80, NIVF sits at the 0.0% percentile with a 14-day RSI of 22.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.28).